510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION MEMORANDUM ASSAY ONLY TEMPLATE

A. 510(k) Number:

K170586

B. Purpose for Submission:

To obtain a substantial equivalence determination for the Strep B Carrot Broth One-Step for the qualitative detection of Group B Streptococcus (GBS).

C. Measurand:

Group B Streptococcus (GBS)

D. Type of Test:

Detection of GBS using selective and differential chromogenic medium

E. Applicant:

Hardy Diagnostics

F. Proprietary and Established Names:

Strep B Carrot BrothTM One-Step

G. Regulatory Information:

1. <u>Regulation section:</u>

21 CFR 866.2360 - Selective culture medium.

2. <u>Classification:</u>

Class I (non-exempt)

3. <u>Product code:</u>

PQZ - GBS culture media, selective and differential

4. <u>Panel:</u>

83 – Microbiology

H. Intended Use:

1. Intended use(s):

Strep B Carrot BrothTM One-Step is a selective and differential medium which is intended for the detection of Group B *Streptococcus* (GBS) from anovaginal specimen collected from pregnant women. The medium is used as an aid in the qualitative determination of GBS colonization in pregnant women. The color change reaction from white to orange is representative of a positive result for presence of GBS. The medium requires 24 hours of incubation but positive results can be interpreted as early as 16 hours. Due to the properties of Strep B Carrot BrothTM One-Step, non-hemolytic GBS cannot be detected by the medium's color change and require subculture for identification. Any presumptive negative indicated by lack of color change at the end of the incubation period must be subcultured to a non-selective medium (e.g. Tryptic Soy Agar with 5% Sheep Blood) to confirm absence of GBS. Subculture must also be performed to recover isolates for conducting susceptibility testing as recommended for penicillin-allergic women.

2. Indication(s) for use:

Same as the Intended Use.

3. <u>Special conditions for use statement(s):</u>

Prescription use only

Strep B Carrot Broth One-Step with no color change after 24 hours incubation is considered presumptive negative for GBS and should be subcultured to non-selective media followed by biochemical testing to rule-out presence of weakly β -hemolytic or non-hemolytic GBS.

Storage of vaginal/rectal swabs in the specified specimen transport systems beyond 24 hours at room temperature before inoculating Strep B Carrot Broth One-Step is not recommended.

4. <u>Special instrument requirements:</u>

Not Applicable

I. Device Description:

Strep B Carrot Broth One-Step is a selective and differential medium used for the detection of *Streptococcus agalactiae* (*S. agalactiae*, (GBS) colonization in pregnant women by testing vaginal/rectal swabs. Color development (light orange, orange, or red-orange color) is a

unique characteristic of β -hemolytic GBS strains resulting from colored pigment production in the presence of substrates such as starch, peptone, serum, and folate pathway inhibitors. Non-hemolytic GBS cannot be detected by color production, but can be recovered from Strep B Carrot Broth One-Step upon subculture to non-selective plates. Growth of microorganisms belonging to other species is either inhibited, or if there is growth, the culture does not produce the expected color reaction.

J. Substantial Equivalence Information:

1. <u>Predicate device name(s)</u>:

Todd Hewitt w/CNA (LIM Broth)

2. <u>Predicate 510(k) number(s):</u>

K871447

3. <u>Comparison with predicate:</u>

	Similarities	
Item	Strep B Carrot Broth One-Step (K170586)	LIM Broth (K871447)
Intended Use	Strep B Carrot Broth [™] One-Step is a selective and differential medium which is intended for the detection of Group B <i>Streptococcus</i> (GBS) from anovaginal specimens collected from pregnant women. The medium is used as an aid in the qualitative determination of GBS colonization in pregnant women. The color change reaction from white to orange is representative of a positive result for presence of GBS. The medium requires 24 hours of incubation but positive results can be interpreted and reported as early as 16 hours. Due to the properties of Strep B Carrot Broth [™] One-Step, non-hemolytic GBS cannot be detected by the medium's color change and require subculture for identification. Any presumptive negative indicated by lack of color change at the end of the incubation period must be subcultured to a non-selective medium (e.g., Tryptic Soy Agar with 5% Sheep Blood) to confirm absence of GBS. Subculture must also be performed to recover isolates for conducting susceptibility testing as recommended for penicillin-allergic women.	Product is used in qualitative procedures to isolate Group B Streptococci from clinical specimens containing mixed bacterial flora.
Specimen Type	Vaginal/rectal swabs	Vaginal/rectal swabs
Inoculation	Direct	Direct
Interpretation	Manual/visual, subculture negatives for confirmation and subculture positives as needed for susceptibility testing	Manual/visual, subculture all to recover colonies for complete identification and susceptibility
Culture Media Type	Selective media	Selective media

Table 1. Comparison with LIM Broth

K. Standard/Guidance Document Referenced (if applicable):

Not Applicable

L. Test Principle:

Strep B Carrot Broth One-Step is a selective, differential medium for the detection of GBS. The ability to detect GBS is based on the presence of selective agents that suppress the growth of organisms other than GBS, and the presence of components necessary for pigment production that allow the detection of GBS colonization based on color development. Vaginal/rectal swabs from antepartum women are inoculated directly into Strep B Carrot Broth One-Step and incubated aerobically at 35°-37°C for 16-24 hours. Positive results can be reported as early as 16 hours. If negative at 16 hours, the broth cultures are re-incubated until 24 hours. The cultures are examined after 24 hours incubation for the development of light orange to orange to orange-red color. After the subculture of negatives to non-selective media, biochemical testing is performed to rule-out the presence of GBS before calling the sample negative.

M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Reproducibility was demonstrated at three sites using a blinded panel of twelve wellcharacterized strains, which included 10 hemolytic GBS strains, 1 non-hemolytic GBS strain, and 1 non-GBS strain as the negative control. At each site, panel members were tested in triplicate at 10^3 CFU/ml with Strep B Carrot Broth One-Step each day for five days. Strep B Carrot Broth One-Step tubes were observed for development of light orange to orange color at 24 hours. Testing was done with at least one operator and two readers. All strains produced the expected results with the Strep B Carrot Broth One-Step at 24 hours >95% of the time for each operator (538/540). All non-hemolytic GBS were recovered upon subculture to Tryptic Soy Agar with 5% sheep blood. Isolates were also plated onto Tryptic Soy Agar with 5% sheep blood to ensure viability and purity of cultures.

b. Linearity/assay reportable range:

Not applicable

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Quality Control (QC) Testing

QC testing was performed at each site to examine color development with Strep B Carrot

Broth One-Step. Five quality control organisms were tested at each study site with Strep B Carrot Broth One-Step for each day of testing. QC testing results provided expected reactions across each testing site (Table 2). The submitted QC data are acceptable.

Organism	Time of	Expected Results after	QC Results (all
	Incubation	24 hrs at 35-37°C	sites)
			Observed/Expected
Streptococcus		Growth; bright	
agalactiae	24 hrs	orange to red color	99/99
ATCC 12386		change	
Streptococcus		Growth; light orange	
agalactiae	24 hrs	color change	99/99
clinical strain			
Streptococcus			
pyogenes ATCC	24 hrs	Growth; no color change	99/99
19615			
Escherichia coli		Partial to complete	
ATCC 25922	24 hrs	inhibition;	99/99
		no color change	
Proteus mirabilis		Partial to complete	
ATCC 12453	24 hrs	inhibition;	99/99
		no color change	

 Table 2: QC Data Summary

Specimen Stability

Various types of specimen transport swabs were evaluated to determine the acceptable storage conditions required to recover GBS from Strep B Carrot Broth One-Step. Swabs were spiked with GBS and a contrived matrix consisting of organisms commonly found in vaginal flora. Eight different GBS strains were used in this study and spiked into contrived matrix near LoD. Organisms suspensitons in the different transport systems were kept at both room temperature and 2-8°C for 0, 24, 48, 72, 96, and 120 hours before inoculation into Strep B Carrot Broth One-Step. TransPRO swabs with Liquid Amies (flocked swab liquid-based transport system) and four other types of transport systems (Sponge-based Liquid Amies and Liquid Stuart's, and Gel-based Amies Gel and Stuart's Gel) were used in this study. Strep B Carrot Broth One-Step was able to recover 8/8 (100%) of GBS strains and produce orange coloration from swabs in Liquid Amies, Liquid Stuart's, Amies Gel, and Stuart's Gel when stored at 2-8°C for up to 96 hours. 100% of GBS strains also produced the expected orange color reaction from TransPRO Liquid Amies stored at 2-8°C for up to 120 hours. Both color development and recovery of GBS were impacted by specimen storage at room temperature beyond 24 hours. All transport systems tested saw a decline in recovery of GBS after 24 hours storage at room temperature as shown in Table 3 below. A limitation in the package insert has been added regarding storage at room temperature beyond 24 hours with the specified specimen transport swabs.

	from Specificity Stored at Room Temperature						
Matuin	Percent Recovery at Room Temperature (%)						
Matrix	24 hrs	48 hrs	72 hrs	96 hrs	120 hrs		
Liquid Amies	100	62.5	37.5	N/A^2	N/A		
Liquid Stuart's	100	62.5	37.5	N/A	N/A		
Amies Gel	100	87.5	87.5	N/A	N/A		
Stuart's Gel	100	87.5	75	N/A	N/A		
TransPRO Liquid Amies	100	87.5	75	12.5	0		

Table 3. Recovery of GBS in Strep B Carrot Broth One-Stepfrom Specimens Stored at Room Temperature

¹Specimens collected in Liquid Amies, Liquid Stuart's, and ESwab Liquid Amies transport systems were evaluated in the clinical studies.

²N/A-Time point not tested for that swab type

d. Detection limit:

Recovery Study

A Recovery Study was performed with two GBS strains (ATCC 12386 and ATCC 12403). After preparing six serial dilutions per strain in natural negative matrix and inoculating media, Strep B Carrot Broth One-Step tubes were incubated to determine color development between 12-24 hours at 35°C. Tube color was recorded at 12 hours and every 2 hours until 24 hours incubation had occurred. At 16 hours, the minimum concentration of GBS detected for both strains with Strep B Carrot Broth One-Step was 10^3 CFU/ml. The LoD for the two GBS strains was confirmed by testing Strep B Carrot Broth One-Step with 20 replicates of each strain at the determined LoD concentration (10^3 CFU/ml).

Analytical Reactivity

A study was conducted to demonstrate the sensitivity of Strep B Carrot Broth One-Step in detecting various GBS strains at a concentration of 10^3 CFU/ml. The study included 54 ATCC reference and clinical GBS strains representing six of the nine different serotypes (48 hemolytic, 6 non-hemolytic). Tubes were read at 24 hours of incubation for an orange color reaction, which was indicative of GBS. The inclusivity panel is shown in Table 4 below.

Strain	Source	Hemolysis	Serotype ¹	Strep B Carrot Broth Observed Color
BAA-611	ATCC	β	V	Orange
12403	ATCC	β	III	Orange
12386	ATCC	β	II	Orange
8017	NCTC	β	III	Orange
1	Clinical	β	V	Orange
2	Clinical	β	II	Orange
KPWP	Clinical	β	III	Orange
P003-001	Clinical	β	Ia	Orange
7	Clinical	β	III	Orange
10	Clinical	β	1a	Orange

Table 4. GBS Panel for Inclusivity Testing

11Clinical β VOrange13Clinical β VIOrange3Clinical β IIOrange4Clinical β VIOrangeQOVHIClinical β IIIOrange27Clinical β IIIOrange28Clinical β IIIOrange14Clinical β IIIOrange15Clinical β IBOrange18Clinical β IbOrange26Clinical β IIOrange29Clinical β IIOrange30Clinical β IBOrangeMS2Clinical β IbOrangeMS3Clinical β IbOrangeMS4Clinical β IbOrangeMS5Clinical β IaOrangeMS6Clinical β IaOrangeMS10Clinical β IaOrangeMS11Clinical β IaOrangeMS13Clinical β IaOrangeMS14Clinical β IaOrangeMS13Clinical β IaOrangeMS14Clinical β IaOrangeMS13Clinical β IaOrangeMS14Clinical β IaOrangeMS13Clinical β IaO					
13 Clinical β VI Orange 3 Clinical β II Orange 4 Clinical β VI Orange QOVHI Clinical β III Orange 27 Clinical β III Orange 28 Clinical β III Orange 14 Clinical β III Orange 15 Clinical β IB Orange 18 Clinical β IB Orange 24 Clinical β II Orange 26 Clinical β IB Orange 30 Clinical β IB Orange MS2 Clinical β Ib Orange MS5 Clinical β Ib Orange MS6 Clinical β Ia Orange MS10 Clinical β Ia Orange MS11 Clinical β Ia Orange	11	Clinical	β	V	Orange
3Clinical $β$ IIOrange4Clinical $β$ VIOrangeQOVHIClinical $β$ IIIOrange27Clinical $β$ IIIOrange28Clinical $β$ IIIOrange14Clinical $β$ IVOrange15Clinical $β$ IIIOrange18Clinical $β$ IbOrange24Clinical $β$ IbOrange25Clinical $β$ IIOrange26Clinical $β$ IIOrange30Clinical $β$ IBOrange33Clinical $β$ IBOrangeMS2Clinical $β$ IbOrangeMS3Clinical $β$ IbOrangeMS4Clinical $β$ IbOrangeMS5Clinical $β$ IaOrangeMS8Clinical $β$ IaOrangeMS10Clinical $β$ IaOrangeMS11Clinical $β$ IaOrangeMS13Clinical $β$ IaOrangeMS14Clinical $β$ IaOrangeMS15Clinical $β$ IaOrangeMS14Clinical $β$ IaOrangeMS15Clinical $β$ IaOrangeMS14Clinical $β$ IaOrangeMS15Clinical $β$ Ia <td< td=""><td>13</td><td>Clinical</td><td>β</td><td>VI</td><td>Orange</td></td<>	13	Clinical	β	VI	Orange
4Clinical $β$ VIOrangeQOVHIClinical $β$ IaLight Orange27Clinical $β$ IIIOrange28Clinical $β$ IIIOrange14Clinical $β$ IVOrange15Clinical $β$ IIIOrange18Clinical $β$ IbOrange24Clinical $β$ IIOrange25Clinical $β$ IIOrange26Clinical $β$ IIOrange30Clinical $β$ IBOrangeMS2Clinical $β$ IBOrangeMS3Clinical $β$ IbOrangeMS4Clinical $β$ IbOrangeMS5Clinical $β$ IbOrangeMS6Clinical $β$ IaOrangeMS7Clinical $β$ IaOrangeMS8Clinical $β$ IaOrangeMS10Clinical $β$ IaOrangeMS12Clinical $β$ IaOrangeMS13Clinical $β$ IaOrangeMS14Clinical $β$ IaOrangeMS15Clinical $β$ IaOrangeMS16Clinical $β$ IaOrangeMS17Clinical $β$ IaOrangeMS13Clinical $β$ IaOrangeMS14Clinical $β$ Ia	3	Clinical	β	II	Orange
QOVHIClinical β IaLight Orange27Clinical β IIIOrange28Clinical β IIIOrange14Clinical β IIIOrange15Clinical β IIIOrange18Clinical β IbOrange24Clinical β IOrange26Clinical β IIOrange30Clinical β IIOrange330Clinical β IBOrangeMS2Clinical β IbOrangeMS3Clinical β IbOrangeMS4Clinical β IbOrangeMS5Clinical β IbOrangeMS6Clinical β IbOrangeMS7Clinical β IaOrangeMS8Clinical β IaOrangeMS10Clinical β IaOrangeMS11Clinical β IaOrangeMS12Clinical β IaOrangeMS13Clinical β IaOrangeMS14Clinical β IaOrangeMS15Clinical β IaOrangeMS14Clinical β IaOrangeMS15Clinical β IaOrangeMS14Clinical β IaOrangeMS26Clinical β <td< td=""><td>4</td><td>Clinical</td><td>β</td><td>VI</td><td>Orange</td></td<>	4	Clinical	β	VI	Orange
27Clinical β IIIOrange28Clinical β IIIOrange14Clinical β IVOrange15Clinical β IIOrange18Clinical β IbOrange19Clinical β IbOrange24Clinical β IIOrange25Clinical β IIOrange29Clinical β IIOrange30Clinical β IIIOrangeMS2Clinical β IbOrangeMS3Clinical β IaOrangeMS4Clinical β IaOrangeMS5Clinical β IbOrangeMS6Clinical β IbOrangeMS7Clinical β IaOrangeMS8Clinical β IaOrangeMS10Clinical β IaOrangeMS12Clinical β IaOrangeMS13Clinical β IaOrangeMS14Clinical β IaOrangeMS15Clinical β IaOrangeMS16Clinical β IaOrangeMS13Clinical β IaOrangeMS14Clinical β IaOrangeMS15Clinical β IaOrangeMS16Clinical β Ia <t< td=""><td>QOVHI</td><td>Clinical</td><td>β</td><td>Ia</td><td>Light Orange</td></t<>	QOVHI	Clinical	β	Ia	Light Orange
28Clinical β IIIOrange14Clinical β IVOrange15Clinical β IIIOrange18Clinical β IbOrange19Clinical β IbOrange24Clinical β IIOrange26Clinical β IbOrange30Clinical β IbOrange30Clinical β IbOrangeMS2Clinical β IbOrangeMS3Clinical β IbOrangeMS4Clinical β IbOrangeMS5Clinical β IbOrangeMS6Clinical β IbOrangeMS7Clinical β IaOrangeMS8Clinical β IaOrangeMS10Clinical β IaOrangeMS11Clinical β IaOrangeMS12Clinical β IaOrangeMS13Clinical β IaOrangeMS14Clinical β IaOrangeMS15Clinical β IaOrangeMS16Clinical β IaOrangeMS17Clinical β IaOrangeMS18ATCC β IbOrangeMS26Clinical β IaOrangeMS26Clinical β IaO	27	Clinical	β	III	Orange
14Clinical β IVOrange15Clinical β IIIOrange18Clinical β 1bOrange19Clinical β IIOrange24Clinical β IIOrange25Clinical β IIOrange29Clinical β IIOrange30Clinical β IIIOrangeMS2Clinical β IIIOrangeMS3Clinical β 1bOrangeMS4Clinical β 1bOrangeMS5Clinical β 1bOrangeMS6Clinical β 1aOrangeMS7Clinical β 1aOrangeMS8Clinical β 1aOrangeMS10Clinical β 1aOrangeMS11Clinical β 1aOrangeMS12Clinical β 1aOrangeMS13Clinical β 1aOrangeMS14Clinical β 1aOrangeMS15Clinical β 1aOrangeMS14Clinical β 1aOrangeMS15Clinical β 1aOrangeMS14Clinical β 1aOrangeMS15Clinical β 1aOrangeMS16Clinical β 1aOrangeMS17Clinical β 1a <td>28</td> <td>Clinical</td> <td>β</td> <td>III</td> <td>Orange</td>	28	Clinical	β	III	Orange
15 Clinical β III Orange 18 Clinical β 1b Orange 19 Clinical β 1b Orange 24 Clinical β II Orange 26 Clinical β II Orange 30 Clinical β III Orange 30 Clinical β III Orange MS2 Clinical β IB Orange MS3 Clinical β 1a Orange MS4 Clinical β 1b Orange MS5 Clinical β 1b Orange MS6 Clinical β 1a Orange MS9 Clinical β 1a Orange MS10 Clinical β 1a Orange MS12 Clinical β 1a Orange MS13 Clinical β 1a Orange MS14 Clinical β 1a Orange M	14	Clinical	β	IV	Orange
18 Clinical $β$ 1b Orange 19 Clinical $β$ 1b Orange 24 Clinical $β$ 11 Orange 26 Clinical $β$ 11 Orange 29 Clinical $β$ 11 Orange 30 Clinical $β$ 11 Orange MS2 Clinical $β$ 11 Orange MS3 Clinical $β$ 1a Orange MS4 Clinical $β$ 1b Orange MS5 Clinical $β$ 1b Orange MS6 Clinical $β$ 1b Orange MS7 Clinical $β$ 1a Orange MS10 Clinical $β$ 1a Orange MS11 Clinical $β$ 1a Orange MS12 Clinical $β$ 1a Orange MS13 Clinical $β$ 1a Orange MS14 Clinical $β$ 1a <t< td=""><td>15</td><td>Clinical</td><td>β</td><td>III</td><td>Orange</td></t<>	15	Clinical	β	III	Orange
19Clinical $β$ 1bOrange24Clinical $β$ IIOrange26Clinical $β$ IbOrange29Clinical $β$ IIOrange30Clinical $β$ IIIOrangeMS2Clinical $β$ IIIOrangeMS3Clinical $β$ IbOrangeMS4Clinical $β$ 1bOrangeMS5Clinical $β$ 1bOrangeMS6Clinical $β$ 1bOrangeMS7Clinical $β$ 1bOrangeMS8Clinical $β$ 1aOrangeMS9Clinical $β$ 1aOrangeMS10Clinical $β$ 1aOrangeMS11Clinical $β$ IaOrangeMS12Clinical $β$ IaOrangeMS13Clinical $β$ 1aOrangeMS14Clinical $β$ 1aOrangeMS12Clinical $β$ 1aOrangeMS13Clinical $β$ 1aOrangeMS14Clinical $β$ 1aOrangeMS15Clinical $β$ 1aOrangeMS16Clinical $β$ 1aOrangeMS17Clinical $β$ 1aOrangeMS16Clinical $β$ 1aOrangeMS17Clinical $β$ 1aOrangeMS16Clinical $β$	18	Clinical	β	1b	Orange
24Clinical β IIOrange26Clinical β 1bOrange29Clinical β IIOrange30Clinical β 1bOrangeMS2Clinical β 1bOrangeMS3Clinical β 1aOrangeMS4Clinical β 1aOrangeMS5Clinical β 1bOrangeMS6Clinical β 1bOrangeMS7Clinical β 1bOrangeMS8Clinical β 1aOrangeMS9Clinical β 1aOrangeMS10Clinical β 1aOrangeMS11Clinical β 1aOrangeMS12Clinical β IIIOrangeMS13Clinical β 1aOrangeMS14Clinical β 1aOrangeMS15Clinical β 1aOrangeMS16Clinical β 1aOrangeMS17Clinical β 1aOrangeMS18ATCC β 1bOrangeMS27Clinical β IIOrangeMS28Clinical β IIOrangeMS29Clinical β IIOrangeMS20ATCCNon-hemolyticIIWhiteMS20ATCCNon-hemolyticIIWhiteMS20ATCCNon-hemoly	19	Clinical	β	1b	Orange
26Clinical β 1bOrange29Clinical β IIOrange30Clinical β 1bOrangeMS2Clinical β 1liOrangeMS3Clinical β 1bOrangeMS4Clinical β 1aOrangeMS5Clinical β 1bOrangeMS6Clinical β 1bOrangeMS7Clinical β 1bOrangeMS8Clinical β 1aOrangeMS9Clinical β 1aOrangeMS10Clinical β 1aOrangeMS11Clinical β 1aOrangeMS12Clinical β 1aOrangeMS13Clinical β 1aOrangeMS14Clinical β 1aOrangeMS15Clinical β 1aOrangeMS17Clinical β 1aOrangeMS18ATCC β 1bOrangeMS26Clinical β 11OrangeMS28Clinical β IIOrangeMS29Clinical β IIOrangeMS20ATCCNon-hemolyticIIWhiteMS20Clinical β IIOrangeMS22Clinical β IIWhiteMS23Clinical β IIWhite	24	Clinical	β	II	Orange
29Clinical β IIOrange30Clinical β 1bOrangeMS2Clinical β 11OrangeMS3Clinical β 1bOrangeMS4Clinical β 1aOrangeMS5Clinical β 1bOrangeMS6Clinical β 1bOrangeMS7Clinical β 1bOrangeMS8Clinical β 1aOrangeMS9Clinical β 1aOrangeMS10Clinical β 1aOrangeMS11Clinical β 1aOrangeMS12Clinical β 1aOrangeMS13Clinical β 1aOrangeMS14Clinical β 1aOrangeMS15Clinical β 1aOrangeMS16Clinical β 1aOrangeMS17Clinical β 1aOrangeMS18ATCC β 1bOrangeMS26Clinical β 11OrangeMS28Clinical β 11OrangeMS29Clinical β 11OrangeMS20ATCCNon-hemolyticIIWhiteMS20Clinical β 11OrangeMS21NCTCNon-hemolyticIIWhiteMS23ClinicalNon-hemolyticIIIMS23ClinicalNon-hem	26	Clinical	β	1b	Orange
30 Clinical β 1bOrangeMS2Clinical β IIIOrangeMS3Clinical β 1bOrangeMS4Clinical β 1aOrangeMS5Clinical β 1bOrangeMS6Clinical β VOrangeMS7Clinical β 1bOrangeMS8Clinical β 1aOrangeMS9Clinical β 1aOrangeMS10Clinical β 1aOrangeMS11Clinical β 1aOrangeMS12Clinical β 1aOrangeMS12Clinical β 1aOrangeMS13Clinical β 1aOrangeMS14Clinical β 1aOrangeMS15Clinical β 1aOrangeMS17Clinical β 1aOrangeMS18ATCC β 1bOrangeMS26Clinical β 1bOrangeMS28Clinical β 1IOrangeMS29Clinical β 1IOrangeMS20ATCCNon-hemolyticIIWhiteMS20ATCCNon-hemolyticIIWhiteMS20ATCCNon-hemolyticIIWhiteMS20Clinical β 1bOrangeMS23Clinical β 1bOrange	29	Clinical	β	II	Orange
MS2Clinical $β$ IIIOrangeMS3Clinical $β$ 1bOrangeMS4Clinical $β$ 1aOrangeMS5Clinical $β$ 1bOrangeMS6Clinical $β$ VOrangeMS7Clinical $β$ 1bOrangeMS8Clinical $β$ 1aOrangeMS9Clinical $β$ 1aOrangeMS10Clinical $β$ 1aOrangeMS11Clinical $β$ 1aOrangeMS12Clinical $β$ IIIOrangeMS12Clinical $β$ 1aOrangeMS13Clinical $β$ 1aOrangeMS14Clinical $β$ 1aOrangeMS15Clinical $β$ 1aOrangeMS14Clinical $β$ 1aOrangeMS15Clinical $β$ 1aOrangeMS16ATCC $β$ 1bOrangeMS17Clinical $β$ 1aOrangeMS18ATCC $β$ 1bOrangeMS26Clinical $β$ 11OrangeMS29Clinical $β$ 11OrangeMS20Clinical $β$ 11OrangeMS20ATCCNon-hemolyticIIWhiteMS20ATCCNon-hemolyticIIWhiteMS20Clinical $β$ 1bOrangeMS21NCTCNon-h	30	Clinical	β	1b	Orange
MS3Clinical $β$ 1bOrangeMS4Clinical $β$ 1aOrangeMS5Clinical $β$ 1bOrangeMS6Clinical $β$ 1bOrangeMS7Clinical $β$ 1bOrangeMS8Clinical $β$ 1aOrangeMS9Clinical $β$ 1aOrangeMS10Clinical $β$ 1aOrangeMS11Clinical $β$ IIIOrangeMS12Clinical $β$ IIIOrangeMS13Clinical $β$ 1aOrangeMS14Clinical $β$ 1aOrangeMS15Clinical $β$ 1aOrangeMS16Clinical $β$ 1aOrangeMS17Clinical $β$ 1aOrangeMS18ATCC $β$ 1bOrangeMS26Clinical $β$ 1bOrangeMS27Clinical $β$ IIOrangeMS20Clinical $β$ IIOrangeMS30Clinical $β$ IIOrangeMS30Clinical $β$ IIOrangeMS20ATCCNon-hemolyticIIIWhiteMS20Clinical $β$ IIWhiteMS21NCTCNon-hemolyticIIIWhiteMS23ClinicalNon-hemolyticIIIWhite	MS2	Clinical	β	III	Orange
MS4Clinical $β$ 1aOrangeMS5Clinical $β$ 1bOrangeMS6Clinical $β$ VOrangeMS7Clinical $β$ 1bOrangeMS8Clinical $β$ 1aOrangeMS9Clinical $β$ 1aOrangeMS10Clinical $β$ 1aOrangeMS11Clinical $β$ IIIOrangeMS12Clinical $β$ IIIOrangeFrenchClinical $β$ 1aOrangeMS13Clinical $β$ IaOrangeMS14Clinical $β$ 1aOrangeMS15Clinical $β$ 1aOrangeMS16Clinical $β$ 1aOrangeMS17Clinical $β$ 1aOrangeMS18ATCC $β$ 1bOrangeMS26Clinical $β$ 1bOrangeMS27Clinical $β$ IIOrangeMS20Clinical $β$ IIOrangeMS30Clinical $β$ IIWhiteMS20ATCCNon-hemolyticIIWhiteMS20Clinical $β$ IIWhiteMS21NCTCNon-hemolyticIIIWhiteMS22ClinicalNon-hemolyticIIIWhite	MS3	Clinical	β	1b	Orange
MS5Clinical $β$ 1bOrangeMS6Clinical $β$ VOrangeMS7Clinical $β$ 1bOrangeMS8Clinical $β$ 1aOrangeMS9Clinical $β$ 1aOrangeMS10Clinical $β$ 1aOrangeMS11Clinical $β$ NT ¹ OrangeMS12Clinical $β$ IIIOrangeMS12Clinical $β$ 1aOrangeMS13Clinical $β$ 1aOrangeMS14Clinical $β$ 1aOrangeMS15Clinical $β$ 1aOrangeMS17Clinical $β$ 1aOrangeMS18ATCC $β$ 1bOrangeMS19ATCC $β$ 1bOrangeMS26Clinical $β$ IIOrangeMS27Clinical $β$ IIOrangeMS28Clinical $β$ IIOrangeMS30Clinical $β$ IIOrangeMS30Clinical $β$ IIOrangeMS30ATCCNon-hemolyticIIWhiteMS20ATCCNon-hemolyticIIWhiteMS21NCTCNon-hemolyticIIIWhiteMS22ClinicalNon-hemolyticIIIWhite	MS4	Clinical	β	1a	Orange
MS6Clinical $β$ VOrangeMS7Clinical $β$ 1bOrangeMS8Clinical $β$ 1aOrangeMS9Clinical $β$ 1aOrangeMS10Clinical $β$ 1aOrangeMS11Clinical $β$ NT ¹ OrangeMS12Clinical $β$ IIIOrangeFrenchClinical $β$ 1aOrangeMS13Clinical $β$ 1aOrangeMS14Clinical $β$ 1aOrangeMS15Clinical $β$ 1aOrangeMS17Clinical $β$ 1aOrangeMS18ATCC $β$ 1bOrangeMS26Clinical $β$ 1bOrangeMS28Clinical $β$ IIOrangeMS29Clinical $β$ IIOrangeMS20ATCCNon-hemolyticIIWhiteMS20ATCCNon-hemolyticIIWhiteMS20Clinical $β$ IIWhiteMS20Clinical $β$ IIWhiteMS20Clinical $β$ IIWhiteMS20Clinical $β$ IIWhiteMS20ClinicalNon-hemolyticIIIWhiteMS20ClinicalNon-hemolyticIIIWhiteMS21NCTCNon-hemolyticIIIWhite	MS5	Clinical	β	1b	Orange
MS7Clinical $β$ 1bOrangeMS8Clinical $β$ 1aOrangeMS9Clinical $β$ 1bOrangeMS10Clinical $β$ 1aOrangeMS11Clinical $β$ NT ¹ OrangeMS12Clinical $β$ IIIOrangeFrenchClinical $β$ IaOrangeMS13Clinical $β$ NTOrangeMS14Clinical $β$ 1aOrangeMS15Clinical $β$ 1aOrangeMS16Clinical $β$ 1aOrangeMS17Clinical $β$ 1aOrangeMS18ATCC $β$ 1bOrangeMS19ATCC $β$ NTOrangeMS26Clinical $β$ IIOrangeMS28Clinical $β$ IIOrangeMS29Clinical $β$ IIOrangeMS30Clinical $β$ IIWhite701348NCIMBNon-hemolyticIIWhiteMS21NCTCNon-hemolyticIIIWhiteMS22ClinicalNon-hemolyticIIIWhite	MS6	Clinical	β	V	Orange
MS8Clinical $β$ 1aOrangeMS9Clinical $β$ 1bOrangeMS10Clinical $β$ 1aOrangeMS11Clinical $β$ NT ¹ OrangeMS12Clinical $β$ IIIOrangeFrenchClinical $β$ 1aOrangeMS13Clinical $β$ 1aOrangeMS14Clinical $β$ 1aOrangeMS15Clinical $β$ 1aOrangeMS16Clinical $β$ 1aOrangeMS17Clinical $β$ 1aOrangeMS18ATCC $β$ 1bOrangeMS19ATCC $β$ 1bOrangeMS26Clinical $β$ IIOrangeMS28Clinical $β$ IIOrangeMS29Clinical $β$ IIOrangeMS30Clinical $β$ IIOrangeMS20ATCCNon-hemolyticIIWhiteMS21NCTCNon-hemolyticIIIWhiteMS23ClinicalNon-hemolyticIIIWhite	MS7	Clinical	β	1b	Orange
MS9Clinical $β$ 1bOrangeMS10Clinical $β$ 1aOrangeMS11Clinical $β$ NT ¹ OrangeMS12Clinical $β$ IIIOrangeFrenchClinical $β$ 1aOrangeMS13Clinical $β$ NTOrangeMS14Clinical $β$ 1aOrangeMS15Clinical $β$ 1aOrangeMS17Clinical $β$ 1aOrangeMS17Clinical $β$ 1aOrangeMS18ATCC $β$ 1bOrangeMS19ATCC $β$ NTOrangeMS26Clinical $β$ IIOrangeMS28Clinical $β$ IIOrangeMS29Clinical $β$ IIOrangeMS30Clinical $β$ IIWhite701348NCIMBNon-hemolyticIIWhiteMS21NCTCNon-hemolyticIIIWhiteMS23ClinicalNon-hemolyticIIIWhite	MS8	Clinical	β	1a	Orange
MS10Clinical $β$ 1aOrangeMS11Clinical $β$ NT ¹ OrangeMS12Clinical $β$ IIIOrangeFrenchClinical $β$ 1aOrangeMS13Clinical $β$ NTOrangeMS14Clinical $β$ 1aOrangeMS15Clinical $β$ 1aOrangeMS17Clinical $β$ 1aOrangeMS18ATCC $β$ 1aOrangeMS19ATCC $β$ 1bOrangeMS26Clinical $β$ IIOrangeMS28Clinical $β$ IIOrangeMS30Clinical $β$ IIOrangeMS30Clinical $β$ IIOrangeMS20ATCCNon-hemolyticIIWhiteMS21NCTCNon-hemolyticIIIWhiteMS23ClinicalNon-hemolyticIIIWhite	MS9	Clinical	β	1b	Orange
MS11Clinical $β$ NT1OrangeMS12Clinical $β$ IIIOrangeFrenchClinical $β$ 1aOrangeMS13Clinical $β$ NTOrangeMS14Clinical $β$ 1aOrangeMS15Clinical $β$ 1aOrangeMS17Clinical $β$ 1aOrangeMS18ATCC $β$ 1aOrangeMS19ATCC $β$ 1bOrangeMS26Clinical $β$ 1bOrangeMS28Clinical $β$ IIOrangeMS30Clinical $β$ IIOrangeMS30Clinical $β$ IIOrangeMS20ATCCNon-hemolyticIIWhite701348NCIMBNon-hemolyticIIIWhiteMS21NCTCNon-hemolyticIIIWhiteMS23ClinicalNon-hemolyticIIIWhite	MS10	Clinical	β	1a	Orange
MS12Clinical $β$ IIIOrangeFrenchClinical $β$ 1aOrangeMS13Clinical $β$ NTOrangeMS14Clinical $β$ 1aOrangeMS15Clinical $β$ 1aOrangeMS17Clinical $β$ 1aOrangeMS18ATCC $β$ 1bOrangeMS19ATCC $β$ 1bOrangeMS26Clinical $β$ 1bOrangeMS28Clinical $β$ IIOrangeMS30Clinical $β$ IIOrangeMS30Clinical $β$ IIOrangeMS20ATCCNon-hemolyticIIWhiteMS20ATCCNon-hemolyticIIWhiteMS20ATCCNon-hemolyticIIWhiteMS21NCTCNon-hemolyticIIIWhiteMS23ClinicalNon-hemolyticIIIWhite	MS11	Clinical	β	NT^1	Orange
FrenchClinical $β$ 1aOrangeMS13Clinical $β$ NTOrangeMS14Clinical $β$ 1aOrangeMS15Clinical $β$ 1aOrangeMS17Clinical $β$ 1aOrangeMS18ATCC $β$ 1bOrangeMS19ATCC $β$ NTOrangeMS26Clinical $β$ 1bOrangeMS28Clinical $β$ IIOrangeMS30Clinical $β$ IIOrangeMS30Clinical $β$ IIOrangeMS20ATCCNon-hemolyticIIWhiteMS20ATCCNon-hemolyticIIWhiteMS21NCTCNon-hemolyticIIIWhiteMS23ClinicalNon-hemolyticIIIWhite	MS12	Clinical	β	III	Orange
MS13Clinical $β$ NTOrangeMS14Clinical $β$ 1aOrangeMS15Clinical $β$ 1aOrangeMS17Clinical $β$ 1aOrangeMS18ATCC $β$ 1bOrangeMS19ATCC $β$ 1bOrangeMS26Clinical $β$ 1bOrangeMS27Clinical $β$ IIIOrangeMS28Clinical $β$ IIOrangeMS30Clinical $β$ IIOrange13813ATCCNon-hemolyticIIWhite701348NCIMBNon-hemolyticIIIWhiteMS21NCTCNon-hemolyticIIIWhiteMS22ClinicalNon-hemolyticIIIWhiteMS23ClinicalNon-hemolyticIIIWhite	French	Clinical	β	1a	Orange
MS14Clinical $β$ 1aOrangeMS15Clinical $β$ 1aOrangeMS17Clinical $β$ 1aOrangeMS18ATCC $β$ 1bOrangeMS19ATCC $β$ NTOrangeMS26Clinical $β$ 1bOrangeMS27Clinical $β$ IIIOrangeMS28Clinical $β$ IIOrangeMS29Clinical $β$ IIOrangeMS30Clinical $β$ IOrange13813ATCCNon-hemolyticIIWhite701348NCIMBNon-hemolyticIIWhiteMS21NCTCNon-hemolyticIIIWhiteMS22ClinicalNon-hemolyticIIIWhiteMS23ClinicalNon-hemolyticIIIWhite	MS13	Clinical	β	NT	Orange
MS15Clinical $β$ 1aOrangeMS17Clinical $β$ 1aOrangeMS18ATCC $β$ 1bOrangeMS19ATCC $β$ NTOrangeMS26Clinical $β$ 1bOrangeMS27Clinical $β$ IIIOrangeMS28Clinical $β$ IIOrangeMS30Clinical $β$ IIOrangeMS30Clinical $β$ IIOrangeMS30Clinical $β$ IIWhite701348NCIMBNon-hemolyticIIWhiteMS20ATCCNon-hemolyticIIIWhiteMS21NCTCNon-hemolyticIIIWhiteMS23ClinicalNon-hemolyticIIIWhite	MS14	Clinical	β	1a	Orange
MS17Clinical $β$ 1aOrangeMS18ATCC $β$ 1bOrangeMS19ATCC $β$ NTOrangeMS26Clinical $β$ 1bOrangeMS27Clinical $β$ IIIOrangeMS28Clinical $β$ IIOrangeMS29Clinical $β$ IIOrangeMS30Clinical $β$ 1bOrange13813ATCCNon-hemolyticIIWhite701348NCIMBNon-hemolyticIIWhiteMS20ATCCNon-hemolyticIIIWhiteMS21NCTCNon-hemolyticIIIWhiteMS23ClinicalNon-hemolyticIIIWhite	MS15	Clinical	β	1a	Orange
MS18ATCC $β$ 1bOrangeMS19ATCC $β$ NTOrangeMS26Clinical $β$ 1bOrangeMS27Clinical $β$ IIIOrangeMS28Clinical $β$ IIOrangeMS29Clinical $β$ IIOrangeMS30Clinical $β$ 1bOrange13813ATCCNon-hemolyticIIWhite701348NCIMBNon-hemolyticIIWhiteMS20ATCCNon-hemolyticIIIWhiteMS21NCTCNon-hemolyticIIIWhiteMS22ClinicalNon-hemolyticIIIWhiteMS23ClinicalNon-hemolyticIIIWhite	MS17	Clinical	β	1a	Orange
MS19ATCC $β$ NTOrangeMS26Clinical $β$ 1bOrangeMS27Clinical $β$ IIIOrangeMS28Clinical $β$ IIOrangeMS29Clinical $β$ IIOrangeMS30Clinical $β$ 1bOrange13813ATCCNon-hemolyticIIWhite701348NCIMBNon-hemolyticIIWhiteMS20ATCCNon-hemolyticIIIWhiteMS21NCTCNon-hemolyticIIIWhiteMS22ClinicalNon-hemolyticIIIWhiteMS23ClinicalNon-hemolyticIIIWhite	MS18	ATCC	β	1b	Orange
MS26Clinical $β$ 1bOrangeMS27Clinical $β$ IIIOrangeMS28Clinical $β$ IIOrangeMS29Clinical $β$ IIOrangeMS30Clinical $β$ 1bOrange13813ATCCNon-hemolyticIIWhite701348NCIMBNon-hemolyticIIWhiteMS20ATCCNon-hemolyticIIIWhiteMS21NCTCNon-hemolyticIIIWhiteMS22ClinicalNon-hemolyticIIIWhiteMS23ClinicalNon-hemolyticIIIWhite	MS19	ATCC	β	NT	Orange
MS27ClinicalβIIIOrangeMS28ClinicalβIIOrangeMS29ClinicalβIIOrangeMS30Clinicalβ1bOrange13813ATCCNon-hemolyticIIWhite701348NCIMBNon-hemolyticIIWhiteMS20ATCCNon-hemolyticIIIWhiteMS21NCTCNon-hemolyticIIIWhiteMS22ClinicalNon-hemolyticIIIWhiteMS23ClinicalNon-hemolyticIIIWhite	MS26	Clinical	β	1b	Orange
MS28Clinical $β$ IIOrangeMS29Clinical $β$ IIOrangeMS30Clinical $β$ 1bOrange13813ATCCNon-hemolyticIIWhite701348NCIMBNon-hemolyticIIWhiteMS20ATCCNon-hemolyticIIIWhiteMS21NCTCNon-hemolyticIIIWhiteMS22ClinicalNon-hemolyticIIIWhiteMS23ClinicalNon-hemolyticIIIWhite	MS27	Clinical	β	III	Orange
MS29ClinicalβIIOrangeMS30Clinicalβ1bOrange13813ATCCNon-hemolyticIIWhite701348NCIMBNon-hemolyticIIWhiteMS20ATCCNon-hemolyticIIIWhiteMS21NCTCNon-hemolyticIIIWhiteMS22ClinicalNon-hemolyticIIIWhiteMS23ClinicalNon-hemolyticIIIWhite	MS28	Clinical	β	II	Orange
MS30Clinicalβ1bOrange13813ATCCNon-hemolyticIIWhite701348NCIMBNon-hemolyticIIWhiteMS20ATCCNon-hemolyticIIIWhiteMS21NCTCNon-hemolyticIIIWhiteMS22ClinicalNon-hemolyticIIIWhiteMS23ClinicalNon-hemolyticIIIWhite	MS29	Clinical	β	II	Orange
13813ATCCNon-hemolyticIIWhite701348NCIMBNon-hemolyticIIWhiteMS20ATCCNon-hemolyticIIIWhiteMS21NCTCNon-hemolyticIIIWhiteMS22ClinicalNon-hemolyticIIIWhiteMS23ClinicalNon-hemolyticNTWhite	MS30	Clinical	β	1b	Orange
701348NCIMBNon-hemolyticIIWhiteMS20ATCCNon-hemolyticIIIWhiteMS21NCTCNon-hemolyticIIIWhiteMS22ClinicalNon-hemolyticIIIWhiteMS23ClinicalNon-hemolyticNTWhite	13813	ATCC	Non-hemolytic	II	White
MS20ATCCNon-hemolyticIIIWhiteMS21NCTCNon-hemolyticIIIWhiteMS22ClinicalNon-hemolyticIIIWhiteMS23ClinicalNon-hemolyticNTWhite	701348	NCIMB	Non-hemolytic	II	White
MS21NCTCNon-hemolyticIIIWhiteMS22ClinicalNon-hemolyticIIIWhiteMS23ClinicalNon-hemolyticNTWhite	MS20	ATCC	Non-hemolytic	III	White
MS22ClinicalNon-hemolyticIIIWhiteMS23ClinicalNon-hemolyticNTWhite	MS21	NCTC	Non-hemolytic	III	White
MS23 Clinical Non-hemolytic NT White	MS22	Clinical	Non-hemolytic	III	White
	MS23	Clinical	Non-hemolytic	NT	White

¹NT= Non-Typable against the nine known serotypes.

In Strep B Carrot Broth One-Step, all 48 β -hemolytic strains produced the expected orange color, and all six non-hemolytic GBS strains showed a negative color reaction. Results also demonstrated that Strep B Carrot Broth One-Step was able to recover all

non-hemolytic GBS strains tested at the LoD (10^3 CFU/ml).

Incubation Study

An Incubation Study was conducted to determine the effect of various incubation times on the performance of Strep B Carrot Broth One-Step when tested with ten GBS strains (hemolytic and non-hemolytic) at 10^3 CFU/ml concentration. The recovery of organisms and development of characteristic color with broth cultures were evaluated every 2 hours from 12-24 hours. At the earliest time point (12 hours), all hemolytic organisms produced some kind of orange color reaction (light orange to orange). All GBS strains, including the non-hemolytic strain tested, were recovered upon subculture of Strep B Carrot Broth One-Step. The earliest incubation time set for positive detection of GBS by color was 16 hours.

e. Analytical specificity:

Cross-Reactivity Study

In order to evaluate the performance of Strep B Carrot Broth One-Step with microorganisms potentially encountered in vaginal/rectal swabs, a Cross-Reactivity Study was completed with 78 non-target organisms (gram negative bacteria, gram positive bacteria, and yeast) at approximately10⁸ CFU/ml. Results showed that all 78 organisms from the cross-reactivity panel produced a negative color reaction with Strep B Carrot Broth One-Step. A total of 45 organisms (57.7%) were recoverable when subcultured at the end of 24 hrs incubation. The cross-reactivity panel is shown in Table 5 below.

Organism					
Acinetobacter baumannii	Enterococcus durans	Proteus mirabilis			
Aeromonas hydrophila	Enterococcus faecalis	Providencia alcalifaciens			
Aspergillus brasiliensis	Enterococcus faecium	Pseudomonas aeruginosa			
Bacillus cereus	Enterococcus flavescens	Pseudomonas fluorescens			
Bacillus subtilis	Enterococcus hirae	Saccharomyces cerevisiae			
Bacteroides fragilis	Enterococcus raffinosus	Salmonella enterica (typhii)			
Bifidobacterium breve	Enterococcus saccharolyticus	Salmonella enterica arizonae			
Campylobacter coli	Escherichia coli	Serratia marcescens			
Campylobacter jejuni	Gardnerella vaginalis	Shigella boydii			
Candida albicans	Geotrichum candidum	Shigella flexneri			
Candida glabrata	Hafnia alvei	Shigella sonnei			
Candida parapsilosis	Klebsiella oxytoca	Staphyloccocus aureus			
Candida tropicalis	Klebsiella pneumoniae	Staphylococcus epidermidis			
Citrobacter brakkii	Lactobacillus acidophilus	Staphylococcus saprophyticus			
Citrobacter freundii	Lactobacillus gasseri	Stenotroph. maltophilia			
Citrobacter koseri	Lactobacillus leichmannii	Streptoccocus mutans			
Clostridium difficile	Lactococcus lactis	Streptococcus anginosus			

Table 5. List of non-target organisms tested in Analytical Specificity Study

Organism				
Clostridium novyi	Legionella pneumophila	Streptococcus bovis		
Clostridium perfringens	Listeria monocytogenes	Streptococcus dysgalactiae		
Clostridium sporogenes	Micrococcus luteus	Streptococcus mitis		
Corynebacterium jekeium	Moraxella cartarrhalis	Streptococcus pneumoniae		
Enterobacter aerogenes	Morganella morganii	Streptococcus pyogenes		
Enterobacter cloacae	Neisseria gonorrhoeae	Streptococcus salivarius		
Enterococcus casseliflavus	Pediococcus acidilacti	Streptococcus uberis		
Enterococcus cecorum	Peptostreptococcus anaerobius	Vibrio parahaemolyticus		
Enterococcus dispar	Plesiomonas shigelloides	Yersinia enterocolitica		

Microbial Interference Study

A Microbial Interference Study was conducted to demonstrate that high levels of nontarget organism will not suppress color development and recover of GBS. All organisms that were recovered upon subculture from Strep B Carrot Broth One-Step in the Analytical Specificity Study were used in the Microbial Interference Study. Additionally, *L. acidophilus* (ATCC 4356) and *E. coli* (ATCC 25922) were included in this study. Non-target organisms at a concentration of 10⁸ CFU/ml were mixed with one hemolytic and one non-hemolytic GBS strain at the LoD. If the target organism was not recovered, the concentration of the non-target organism was lowered 10-fold until the target organism was recovered.

At 24 hrs, both GBS strains (*S. agalactiae*, ATCC 12386 and *S. agalactiae*, ATCC 13813) gave the expected results in the presence of 10^8 CFU/ml of all non-target strains in the Microbial Interference Study, except in the presence of *Enterococcus faecalis* (ATCC 29212). In the presence of *E. faecalis*, proper color development with the β -hemolytic GBS strain (ATCC 12386) was observed at 10^5 CFU/ml or lower. For the non-hemolytic GBS strain (ATCC 13813) tested, it was recovered upon subculture when the concentration of *E. faecalis* was 10^6 CFU/ml or lower. The potential for high concentrations of *E. faecalis* to inhibit the detection and recovery of GBS is noted as a Limitation in the device labeling.

f. Assay cut-off:

Not Applicable

2. Comparison studies:

a. Method comparison with predicate device:

Not Applicable. Compared to Standard Reference Method

b. Matrix comparison:

Not Applicable

3. Clinical studies:

a. Clinical Sensitivity:

Strep B Carrot Broth One-Step was evaluated at four clinical sites. A total of 884 vaginal/rectal swabs from pregnant women were prospectively collected. Due to protocol deviations (enrollment criteria not met), 108 specimens were excluded from the study leaving 776 swab specimens to be inoculated and incubated in Strep B Carrot Broth Kit. An additional 5 samples were excluded due to improper storage (time of set-up) before enrichment. In total, 771 compliant specimens were included in the final performance calculations.

A 30 μ l aliquot of the clinical specimen in transport media was used to inoculate Strep B Carrot Broth One-Step, and the culture was incubated at 35-37°C for 24 hours. The samples included in the evaluation of performance consisted of 771 specimens obtained in three different types of transport swabs/media—Liquid Stuart's Sponge (n=284), Liquid Amies Sponge (n=111), and Liquid Amies ESwab (n=376). For the Reference Culture Method, vaginal/rectal specimens were tested by inoculating LIM Broth with 30 μ l of specimen from the transport swab system and incubating for 24 hours at 35-37°C. Turbid LIM Broth cultures were subcultured to Tryptic Soy Agar with 5% Sheep Blood, and all colonies with characteristic appearance suggestive of GBS were screened to confirm the presence of GBS (both hemolytic and non-hemolytic strains) using established laboratory methods: gram stain, catalase, latex agglutination.

Color development after enrichment in Strep B Carrot Broth One-Step was observed after 24 hours. The Strep B Carrot enriched broth culture (regardless of color development) was also subcultured to Tryptic Soy Agar with 5% Sheep Blood using a 10 μ l loop, and the agar plate was incubated for 24 hours at 35-37°C in a CO₂ enriched environment. All colony types were submitted for identification. Results of Strep B Carrot Broth One-Step at 24 hours incubation were compared to the Reference Culture Method. The color change from white to orange with Strep B Carrot Broth One-Step was representative of a positive result for the presence of GBS. Tables 7-9 below show the clinical performance data for Strep B Carrot Broth One-Step vs the Reference Culture Method (all sites). Performance (sensitivity and specificity) of Strep B Carrot Broth One-Step was calculated based on color development and the recovery of GBS from the medium and compared to the recovery of β-hemolytic GBS and total GBS strains by the Reference Culture Method.

All isolates with discrepant results were frozen in CryoSavers with Brucella Broth and returned to Hardy Diagnostics for testing. The identity of each isolate was confirmed (β -hemolytic GBS, non-hemolytic GBS, or non-GBS isolate). Once the identity was confirmed, positive organisms (β -hemolytic GBS or non-hemolytic GBS) were tested at LoD (10^3 CFU/ml) in donated negative-vaginal rectal matrix for their recovery from the LIM Culture Reference Method, color development in Strep B Carrot Broth One-Step, and recovery from the Strep B Carrot Broth One-Step + Subculture method.

(Recovery of an ODS) is Reference Calcure Method (an ODS)					
Strep B Carrot	Reference Culture Method				
Broth One-Step					
Plus Subculture	Positive	Negative	Total		
(24 hrs)		-			
Positive	161	11	172		
Negative	2	597	599		
Total	Total 163 608 771				
Sensitivity: 98.8% (161/163), 95% CI (95.6%-99.7%)					
Specificity: 98.2% (597/608), 95% CI (96.8%-99.0%)					

 Table 7. Comparison between Strep B Carrot Broth One-Step + Subculture (Recovery of all GBS) vs Reference Culture Method (all GBS)

Table 8. Comparison between Strep B Carrot Broth One-Step (color) vs
Reference Culture Method (all GBS)

Strep B Carrot	Reference Culture Method					
Broth One-Step						
Plus Subculture	Positive	Negative	Total			
(24 hrs)						
Positive	143	8 ¹	151			
Negative	20^{2}	600	620			
Total	163	608	771			
Sensitivity: 87.7% (143/163), 95% CI (81.8%-91.9%)						

Specificity: 98.7% (600/608), 95% CI (97.4%-99.3%)

¹ There were 8 False Positives observed. All isolates were re-tested and confirmed at Hardy Diagnostics using the discrepant analysis protocol described above. Of these, six isolates were originally negative by LIM reference method, showed a positive color reaction in Strep B Carrot Broth One-Step, and were confirmed to be β -hemolytic when subcultured on Blood Agar. One was not able to be confirmed because no GBS isolate was frozen and the remaining specimen had β hemolytic colonies present on the blood agar plates; however, Proteus swarmed the plates, preventing the technician from isolating the β -hemolytic colonies for identification. ² There were 20 False Negatives observed. All isolates were re-tested and confirmed at Hardy Diagnostics using the discrepant analysis protocol described above. Fourteen of the β Group B Streptococci isolates recovered from LIM, but originally gave a negative Strep B Carrot Brot One-Step color reaction, were confirmed as β Group B Streptococci and subsequently confirmed to have a positive Strep B Carrot Broth One-Step color reaction at LoD. Two isolates were identified as very weak β Group B Streptococci and did not produce the expected color reaction in Strep B Carrot Broth One-Step. Four isolates were confirmed as non-hemolytic Group B Streptococci with a negative color reaction in Strep B Carrot Broth One-Step.

Kelerence Culture Method (only p-nemorytic ODS)					
Strep B Carrot	Refe	Reference Culture Method			
Broth One-Step					
Plus Subculture	Positive	Negative	Total		
(24 hrs)		_			
Positive	141	10	151		
Negative	15	605	620		
Total	Total 156 615 771				
Sensitivity: 90.4% (141/156), 95% CI (84.7%-94.1%)					
Specificity: 98.4% (605/615), 95% CI (97.0%-99.1%)					

Table 9. Comparison between Strep B Carrot Broth One-Step (color) vsReference Culture Method (only β-hemolytic GBS)¹

¹Considering that non-hemolytic GBS cannot be detected by the medium's color change and require subculture for identification, there were 5 specimens that were found to be non-hemolytic. If these specimens are included as negatives, then the overall sensitivity and specificity values observed when comparing the recovery of β -hemolytic GBS by the LIM Reference Method to the Strep B Carrot Broth One-Step color development can also be evaluated.

b. Clinical specificity:

See above

c. Other clinical supportive data (when a. and b. are not applicable):

Not Applicable

4. <u>Clinical cut-off</u>:

Not Applicable

5. Expected values/Reference range:

The overall prevalence of GBS (both hemolytic and non-hemolytic strains) by the Reference Culture Method was 21.1% (163/771).

N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.